1. Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to hepatitis C virus seroprevalence. Hepatology. 2013;57(4):1333-1342.
2. Hepatitis C: fact sheet no. 164. Geneva: World Health Organization, 2012 Available at: http://www.who.int/mediacentre/factsheets/fs164/en Access Date: 10th February 2013.
3. Dilsiz G, Yenicesu I, Belen FB, Celik B, Ozturk G. Trends in hepatitis B and hepatitis C virus seropositivity among blood donors over 15 years screened in the blood bank of a university hospital. Transfus Apher Sci. 2012;47(1):95-100.
4. Mıstık R. Hepatit C Virüs enfeksiyonunun epidemiyolojisi. In: Tabak F, Tosun S,eds. Viral Hepatit 2013. İstanbul Tıp Kitabevi, İstanbul 2013;pp 81-112.
5. Guner R, Kocak Tufan Z, Guven T, Hacıosmanoglu D, Yilmaz GR, Tasyaran MA. Hepatit C tedavisinde PEG IFN/RBV ile yüksek EVY düşük KVY. XII. Ulusal Hepatit Kongresi Antalya 2014. Abstract.
6. Guner R, et al. Kronik Hepatit C Enfeksiyonunda Tedavisiz İzlem Nedenleri: Çok Merkezli Çalışma XII. Ulusal Hepatit Kongresi Antalya 2014. Abstract.
7. Dogan UB, Atabay A, Akin MS, Yalaki S. The comparison of the efficacy of pegylated interferon α-2a and α-2b in chronic hepatitis C patients with genotype 1. Eur J Gastroenterol Hepatol. 2013;25(9):1082-1085.
8. Di Bisceglie A, et al. Virologic Outcomes and Adherence to Treatment Algorithms in a Longitudinal Study of Patients with Chronic Hepatitis C Treated with Boceprevir (BOC) or Telaprevir (TVR) in the United States (HCV-TARGET). 64th Annual Meeting of the American Association for the Study of Liver diseases, November 1-5, 2013, Washington,USA; abstract 41.
9. Zeuzem S1, Andreone P, Pol S, Lawitz E, Diago M, Roberts S, Focaccia R, Younossi Z, Foster GR, Horban A, Ferenci P, Nevens F, Müllhaupt B, Pockros P, Terg R, Shouval D, van Hoek B, Weiland O, Van Heeswijk R, De Meyer S, Luo D, Boogaerts G, Polo R, Picchio G, Beumont M; REALIZE Study Team. Telaprevir for treatment of HCV infection. N Eng J Med. 2011;362:2417-2428.
10. Forns X, et al. Simeprevir (TMC435) with peg-interferon α-2a/ribavirin for treatment of chronic HCV genotype 1 infection in patients who relapsed after previous interferon-based therapy: efficacy and safety in patient sub-populations in the PROMISE phase III tria64th Annual Meeting of the American Association for the Study of Liver diseases, November 1-5, 2013, Washington, USA; abstract 1092.
11. Jacobson I, et al. STARTVerso3: A randomized, double-blind, placebo-controlled Phase III trial of faldaprevir in combination with pegylated interferon alfa-2a and ribavirin in treatment-experienced patients with chronic hepatitis C genotype-1 infection. 64th Annual Meeting of the American Association for the Study of Liver diseases, November 1-5, 2013, Washington, USA; abstract 1100.
12. Zeuzem S, et al. Sofosbuvir + Ribavirin for 12 or 24 Weeks for Patients with HCV Genotype 2 or 3: the VALENCE trial. 64th Annual Meeting of the American Association for the Study of Liver diseases, November 1-5, 2013, Washington, USA; abstract 1085.
13. Jacobson I, et al. SVR results of a once-daily regimen of simeprevir (TMC435) plus sofosbuvir (GS-7977) with or without ribavirin in cirrhotic and non-cirrhotic HCV genotype 1 treatment-naïve and prior null responder patients: The COSMOS study. 64th Annual Meeting of the American Association for the Study of Liver diseases, November 1-5, 2013, Washington, USA; abstract LB3.
14. Dufour JF, et al. Interferon-Free Treatment with Faldaprevir, Deleobuvir (BI 207127) and Ribavirin in SOUND-C3: 95% SVR12 in HCV-GT1b. 64th Annual Meeting of the American Association for the Study of Liver diseases, November 1-5, 2013, Washington, USA; abstract 1102.
15. Gane E, et al., Once Daily Sofosbuvir/Ledipasvir Fixed Dose Combination with or without Ribavirin: Data from the ELECTRON trial. 64th Annual Meeting of the American Association for the Study of Liver diseases, November 1-5, 2013, Washington, USA; abstract 73.
16. Lawitz E, et al. Once Daily Sofosbuvir/Ledipasvir Fixed Dose Combination with or without Ribavirin Resulted in ≥95% Sustained Virologic Response In Patients with HCV Genotype 1,Including Patients with Cirrhosis: the LONESTAR trial. 64th Annual Meeting of the American Association for the Study of Liver diseases, November 1-5, 2013, Washington, USA; abstract 215.
17. Sosyal güvenlik kurumu sağlık uygulama tebliğinde değişiklik yapılmasına dair tebliğ. Resmî Gazete Sayı : 2877726 Eylül 2013.
18. Sulkowski M, et al. All-Oral Therapy With Sofosbuvir Plus Ribavirin For the Treatment of HCV Genotype 1, 2, and 3 Infection in Patients Co-infected With HIV (PHOTON-1). 64th Annual Meeting of the American Association for the Study of Liver diseases, November 1-5, 2013, Washington ,USA; abstract 212.
19. Charlton MA, et al. Sofosbuvir and Ribavirin for the Treatment of Established Recurrent Hepatitis C Infection After LiverTransplantation: Preliminary Results of a Prospective, Multicenter Study. 64th Annual Meeting of the American Association for the Study of Liver diseases, November 1-5, 2013, Washington,USA; abstract LB2.
20. Poordad F, McCone J Jr, Bacon BR, Bruno S, Manns MP, Sulkowski MS, Jacobson IM, Reddy KR, Goodman ZD, Boparai N, DiNubile MJ, Sniukiene V, Brass CA, Albrecht JK, Bronowicki JP; SPRINT-2 Investigators. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med. 2011;364(13):1195-1206.
21. De Meyer S, Dierynck I, Ghys A, Beumont M, Daems B, Van Baelen B, Sullivan JC, Bartels DJ, Kieffer TL, Zeuzem S, Picchio G. Characterization of telaprevir treatment outcomes and resistance in patients with prior treatment failure: results from the REALIZE trial. Hepatology. 2012;56(6):2106-2115.
22. Manns MP, McCone J Jr, Davis MN, Rossaro L, Schiff E, Shiffman ML, Bacon B, Bourliere M, Sulkowski MS, Bruno S, Balart L, Bronowicki JP, Kwo P, Poordad F, Felizarta F, Reddy KR, Helmond FA, Sings HL, Pedicone LD, Burroughs M, Brass CA, Albrecht JK, Vierling JM. Overall safety profile of boceprevir plus peginterferon alfa-2b and ribavirin in patients with chronic hepatitis C genotype 1: a combined analysis of 3 phase 2/3 clinical trials. Liver Int. 2014;34(5):707-719.
23. Guner R, Tufan ZK. Telaprevir use in a chronic hepatitis C patient with hemophilia. Eur J Gastroenterol Hepatol. 2014;26(2):248.
24. Cacoub P, Bourliere M, Lübbe J, Dupin N, Buggisch P, Dusheiko G, Hezode C, Picard O, Pujol R, Segaert S, Thio B, Roujeau JC. Dermatologic side effects of hepatitis c and its treatment; patient menagement in the era of direct-acting antivirals. J Hepatol. 2012;56:455-463.
25. Frellick M. New Interferon-Free Drugs for Hep C Show High Cure Rates. Available at: http://www.medscape.com/viewarticle/821393 Acess date: 18 th March 2014.
26. Lawitz E, Hezode C, Varunok P, Thuluvath PJ, Baykal T, Kapoor M,Lovell SS, Wang T, Pilot-Mathias T, Vilchez RA, Bernstein B. Interferon- and Ribavirin-free Regimen of ABT-450/r + ABT-267 in HCV Genotype 1b-infected Treatment-naive Patients and Prior Null Responders. 64th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD 2013). Washington, DC, November 1-5, 2013. Abstract 74.
27. Kohli A, et al. Combination Oral, Ribavirin Free, Antiviral Therapy to Optimize Treatment Outcomes for Hepatitis C GT-1 Treatment Naïve Patients: Interim Results from the NIAID SYNERGY Trial. 64th Annual Meeting of the American Association for the Study of Liver diseases, November 1-5, 2013, Washington, USA; abstract LB8.
28. Sulkowski M, et al. All-Oral Therapy With Sofosbuvir Plus Ribavirin For the Treatment of HCV Genotype 1, 2, and 3 Infection in Patients Co-infected With HIV (PHOTON-1). 64th Annual Meeting of the American Association for the Study of Liver diseases, November 1-5, 2013, Washington, SA; abstract 212.
29. World Health Organization. Guidelines for the screening, care and treatment of persons with hepatitis C infection. April 2014.
30. Phase III HIV/HCV Co-Infection Daclatasvir (DCV)+ Sofosbuvir (SOF) (ALLY 2)Sof. Available at: http//www.clinicaltrials.gov (ClinicalTrials.gov Identifier:NCT02032888) Acess date: 18 th March 2014.
31. Curry MP, et al.,Pretransplant Sofosbuvir and Ribavirin to Prevent Recurrence of HCV Infection after Liver Transplantation 64th Annual Meeting of the American Association for the Study of Liver diseases, November 1-5, 2013, Washington, USA; abstract 213.
32. Charlton MA, et al. Sofosbuvir and Ribavirin for the Treatment of Established Recurrent Hepatitis C Infection After LiverTransplantation: Preliminary Results of a Prospective, Multicenter Study. 64th Annual Meeting of the American Association for the Study of Liver diseases, November 1-5, 2013, Washington,USA; abstract LB2.
33. Hagan LM, Sulkowski MS, Schinazi RF. Cost analysis of sofosbuvir/ribavirin versus sofosbuvir/simeprevir for genotype 1 HCV in interferon ineligible/intolerant individuals. Hepatology. 2014;60(1):37-45.
34. Telaprevir Patient Assistance Program. Available at: http://www.natap.org/ Acess date: 18th March 2014.
35. Boceprevir&Peginterferon Patient Assistance Programs. Available at: http://www.natap.org/ Acess date: 18th March 2014.